Biopharmaceutical company Akeso Inc (HK:9926) announced on Thursday that the first patient has been enrolled in the Phase I clinical trial of AK138D1 for the treatment of advanced malignancies in Australia.
AK138D1 is a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate), and is the company's first ADC drug to enter clinical studies.
Akeso's self-developed, first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), have both received regulatory approval and are now available to patients in China.
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
Dermata Therapeutics completes treatment in XYNGARI Phase 3 acne trial
Bloom Science's BL-001 shows positive results in Phase 1 trial
Heyou Hospital, China orders treatment planning system from RaySearch
ONWARD Medical secures funding to advance Parkinson's disease research
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
Raziel and Fosun Pharma commence phase 3 RZL-012 study in China
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
Protagonist and Takeda report positive Phase 3 results for rusfertide in polycythemia vera
GSK demonstrates significant improvement in CRSwNP treatment with depemokimab at 2025 AAAAI
Australia declines approval for BioArctic and Eisai's Alzheimer's drug lecanemab